Yoshihiko Kiyasu

TL;DR: In this article, the authors collected additional nasopharyngeal samples from patients who had already tested positive for SARS-CoV-2 by reverse transcription PCR and used the swab for an antigen test, QuickNavi™-COVID19 Ag, and the time periods to get positive results were measured.

TL;DR: In this paper , the authors collected additional nasopharyngeal samples from patients who had already tested positive for SARS-CoV-2 by reverse transcription PCR and used the swab for an antigen test, QuickNavi™-COVID19 Ag, and measured the time periods to get positive results.

TL;DR: In this paper , a novel digital immunoassay (RapidTesta SARS-CoV-2) was proposed for the detection of infectious disease pathogens, but there have been insufficient data concerning SARS co-v-2 Immunoassays.

TL;DR: In this article, a novel digital immunoassay (RapidTesta SARS-CoV-2) was proposed for the detection of infectious disease pathogens, but there have been insufficient data concerning SARS CoV2 immuno assays.

TL;DR: The causative organism, recovered from the pericardial effusion, was unidentifiable with commercial systems but determinable with molecular methods at the subspecies level and the patient fully improved with pericardiocentesis and subsequent administration of ciprofloxacin for a total of four weeks.